Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma. [electronic resource]
Producer: 20191104Description: 161-169 p. digitalISSN:- 1872-7980
- Adipose Tissue -- cytology
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Brain Neoplasms -- drug therapy
- Cell Survival -- drug effects
- Chemotherapy, Adjuvant
- Coculture Techniques
- Female
- Genetic Therapy -- methods
- Glioma -- drug therapy
- Histone Deacetylase Inhibitors -- pharmacology
- Humans
- Male
- Mesenchymal Stem Cell Transplantation
- Mesenchymal Stem Cells -- metabolism
- Mice, Inbred BALB C
- Mice, Nude
- Middle Aged
- Panobinostat -- pharmacology
- Phenotype
- Signal Transduction
- TNF-Related Apoptosis-Inducing Ligand -- genetics
- Tumor Burden -- drug effects
- Tumor Cells, Cultured
- Tumor Necrosis Factor Decoy Receptors -- metabolism
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.